VivoSim Labs, Inc. Equity Securities, FV-NI, Unrealized Loss
VivoSim Labs, Inc. (VIVS) reported Equity Securities, FV-NI, Unrealized Loss of $100.00 thousand for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2023-02-09
- VivoSim Labs, Inc. equity securities, fv-ni, unrealized loss for the quarter ending 2022-12-31 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $100.00K 10-Q · filed 2023-02-09 | |
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |